Audrey Sternberg

August 31, 2022

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

June 13, 2022

Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.

March 18, 2022

Patients with metastatic renal cell carcinoma have multiple effective frontline treatment options.

December 09, 2021

Findings from a pooled efficacy and safety analysis support the use of palbociclib plus endocrine therapy in patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer.

September 09, 2021

Selectively targeting the EGFR exon insertion mutations was associated with improved outcomes in patients with previously treated non-small cell lung cancer.

April 20, 2021

A poster presentation from the Oncology Nursing Society’s 46th Annual Congress describes a single-center clinician education program aimed at improving patient satisfaction.

September 14, 2020

As the impact of the coronavirus disease 2019 (COVID-19) pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.

January 29, 2019

Neoadjuvant chemotherapy with dose-dense MVAC extends overall survival compared with other chemo regimens in bladder cancer treated with cystectomy.

August 17, 2018

The addition of tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, to weekly paclitaxel (Taxol) appeared safe in the treatment of patients with platinum-resistant ovarian cancer.

August 10, 2018

As abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, the oncology nurse is now a key factor for these patients, according to Paula Fulgham, RN, OCN.